Health economics and the value of therapy in Alzheimer's disease

Alzheimer's and Dementia

Volumn 3, Issue 3, 2007, Pages 143-151

  Schwam, Elias M ^a   Abu Shakra, Susan ^b   del Valle, Megan ^a   Townsend, Raymond J ^c   Carrillo, Maria C ^d   Fillit, Howard ^e  

^a PFIZER INC   (United States)

^b ALLERGAN INC   (United States)

^c ELAN PHARMACEUTICALS   (United States)

^d ALZHEIMER'S ASSOCIATION   (United States)

^e Alzheimers Drug Discovery Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE; NOOTROPIC AGENT; PIRACETAM;

ALZHEIMER DISEASE; CAREGIVER BURDEN; COGNITIVE DEFECT; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG CHOICE; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITALIZATION COST; HUMAN; MEDICARE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT;

EID: 34249689203     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.04.391     Document Type: Editorial

References (57)

1. Wimo A., Jonsson L., and Winblad B. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dementia 3 (2007) 81-91
2. Knapp M. Economic outcomes and levers. impacts for individuals and society. Int Psychogeriatr IPA 19 (2007) 483-495
3. Wu G., Lanctôt K.L., Herrmann N., Moosa S., and Oh P.I. The cost-benefit analysis of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. CNS Drugs 17 (2003) 1045-1057
4. Koppel R. Alzheimer's disease: the costs to US businesses in 2002. Prepared for the Alzheimer's Association. Available at: http://www.alz.org/national/documents/062602ADCosts.pdf.
5. Alzheimer's disease facts and figures 2007. Available at: http://www.alz.org/news_and_events_rates_rise.asp.
6. Hill J.W., Futterman R., Duttagupta S., Mastey V., Lloyd J.R., and Fillit H. Alzheimer's disease and related dementias increase costs of co-morbidities in managed Medicare. Neurology 58 (2002) 62-70
7. Torian L., Davidson E., Fulop G., Sell L., and Fillit H. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr 4 (1992) 231-239
8. Fillit H., Hill J.W., and Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage and pharmacotherapy. Fam Med 34 (2002) 528-535
9. Hill J., Fillit H., Thomas S., and Chang S. Functional impairment, healthcare costs, and the prevalence of institutionalization in patients with Alzheimer's disease and other dementias. Pharmacoeconomics 24 (2006) 265-280
10. Callahan C.M., Hendrie H.C., and Tierney W.M. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 122 (1995) 422-429
11. Fillit H., Geldmacher D.S., Welter R.T., Maslow K., and Frazer M. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 50 (2002) 1871-1878
12. Hughs C. ICD-9 changes. the new codes are here. Fami Pract Manage 13 (2006) 8
13. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost effectiveness in health and medicine (1996), Oxford University Press, Oxford
14. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization?. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146 (1992) 473-481
15. Neumann P.J., Hermann R.C., and Kuntz K.M. Cost effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52 (1999) 1138-1145
16. Neumann P.J. Using cost effectiveness analysis to improve health care: opportunities and barriers (2005), Oxford University Press, New York
17. Bosanquet N., and Yeates A. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 24 (2006) 623-625
18. Atlas RF. The role of PBMs in implementing the Medicare prescription drug benefit. Health Affairs (Project Hope) 2004; (Suppl. Web Exclusives).W4-504-15.
19. Mullins C.D., and Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Pharmacoeconomics 20 (2002) 9-21
20. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593
21. Loveman E., Green C., Kirby J., Takeda A., Picot J., Payne E., et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and Memantine for Alzheimer's disease. Health Technol Assess 10 (2006) 1-160
22. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., and van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. Br Med J [Clin Res] 331 (2005) 321-327
23. Takeda A., Loveman E., Clegg A., Kirby J., Picot J., Payne E., et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21 (2006) 17-28
24. Osterhaus J.T., and Townsend R.J. Incorporating pharmacoeconomics research into clinical trials. In: Bootman J.L., Townsend R.J., and McGhan W.F. (Eds). Principles of pharmacoeconomics. 3rd ed. (2005), Harvey Whitney Books, Cincinnati
25. Birks J., and Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD001190
26. Trinh N.H., Hoblyn J., Mohanty S., and Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289 (2003) 210-216
27. Lanctôt K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assoc J 169 (2003) 557-564
28. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 677-685
29. Stern Y., Albert S.M., Sano M., Richards M., Miller L., Folstein M., et al. Assessing patient dependence in Alzheimer's disease. J Gerontol 49 (1994) M216-M222
30. Neumann P.J. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. J Clin Psychiatry 60 Suppl. 3 (1999) 9-14
31. Caro J.J. Pharmacoeconomic analysis using discrete event simulation. Pharmacoeconomics 23 (2005) 323-332
32. Jönsson L., Lindgren P., Wimo A., Jonson B., and Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 21 (1999) 1230-1240
33. Kulasingam S.L., Smasa G.P., Zarin D.A., Rutschmann O.T., Patwardhan M.B., McCrory D.C., et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia?. A decision analysis. Value Health J Int Soc Pharmacoecon Outcomes Res 6 (2003) 542-550
34. Kinosian B.P., Stallard E., Lee J.H., Woodbury M.A., Zbrozek A.S., and Glick H.A. Predicting 10-year care requirements for older people with suspected Alzheimer's disease. J Am Geriatr Soc 48 (2000) 631-638
35. Caro J.J., Salas M., Ward A., Getsios D., Mehnert A., and AHEAD Study Group. Assessment of health economics in Alzheimer's disease. Dementia Geriatr Cogn Disord 12 (2002) 84-89
36. Lu S., Hill J., and Fillit H. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large Medicare managed care plan: a case-controlled study. Am J Geriatr Pharmacother 3 (2005) 92-102
37. Fillit H., and Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 3 (2005) 39-49
38. Wimo A., Winblad B., Stoffler A., Wirth Y., and Mobius H.J. Resource utilization and cost analysis of Memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21 (2003) 327-340
39. Heckman J. Sample selection bias as a specification error. Econometrica 47 (1979) 153-161
40. Wimo A. Dementia (2006), Swedish Council on Technology Assessment in Health Care, Stockholm [English version in press]
41. Wimo A., and Norlund A. Cost-effectiveness of treatments for Alzheimer's dementia. Expert Rev Pharmacoecon Outcomes Res 7 (2007) 83-90
42. Draft guidance for industry on patient-reported outcome measures. use in medical product development to support labeling claims. Fed Register 71 (2006) 5862-5863
43. Rockwood K., Fay S., Song X., MacKnight C., and Gorman M. Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. Can Med Assoc J 174 (2006) 1099-1105
44. Ready R. Patient reported outcomes in clinical trials for Alzheimer's disease. Alzheimers Dement 3 (2007) 172-176
45. Logsdon R.G., Gibbons L.E., McCurry S.M., and Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med 64 (2002) 510-519
46. Selai C.E., Trimble M.R., Rossor M., and Harvey R.J. Assessing quality of life in dementia: preliminary psychometric testing of the Quality of Life Assessment Schedule (QOLAS). Neuropsycholog Rehabil 11 (2001) 219-243
47. Ready R.E., Ott B.R., Grace J., and Fernandez I. The Cornell-Brown scale for quality of life in dementia. Alzheimer Dis Assoc Disord 16 (2002) 109-115
48. Ready R.E., Ott B.R., and Grace J. Patient versus informant perspectives of quality of life in mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004) 256-265
49. Sands L.P., Ferreira P., Stewart A.L., Brod M., and Yaffe K. What explains differences between dementia patients' and their caregivers' ratings of patient's quality of life?. Am J Geriatr Psychiatry 12 (2004) 272-280
50. Ready R.E., Ott B.R., and Grace J. Insight and self-reported QOL from memory disorder patients. Am J Alzheimers Dis 21 (2006) 242-248
51. Smith S.C., Lamping D.L., Banerjee S., Harwood R., Foley B., Smith P., et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 9 (2005) 1-93
52. Smith S., Lamping D., Banerjee S., Harwood R.H., Foley B., Smith P., et al. The development of a new measure of health related quality of life for people with dementia: DEMQOL. Psychol Med 37 (2007) 737-746
53. Banerjee S., Smith S.C., Lamping D.L., Harwood R.H., Foley B., Smith P., et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry 77 (2006) 146-148
54. Banerjee S., Willis R., Matthews D., Contell F., Chan J., and Murray J. Improving the quality of dementia care-an evaluation of the Croydon memory service model. Int J Geriatr Psychiatry (2007) Jan 23 [Epub ahead of print]
55. Schulz R., and Beach S. Caregiving as a risk factor for mortality. The Caregiver Health Effects Study. JAMA 282 (1999) 2215-2219
56. Schulz R., and Martire L.M. Family caregiving in persons with dementia: prevalence, health effects, and support strategies. Am J Geriatr Psychiatry 12 (2004) 240-249
57. Schulz R., Hebert R.S., Dew M.A., Brown S.L., Scheier M.F., Beach S.R., et al. Patient suffering and caregiver compassion: new opportunities for research, practice and policy. Gerontologist 47 (2007) 4-13